ExpreS2ion to present in upcoming investor events
Hørsholm, Denmark, 10 September 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events, including Investing in Life Science: From Seed to Success and a Danish Stock seminar for institutional investors.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below.
12 September 2024 | Investing in Life Science: From Seed to Success, hosted by BioStock and Vator Securities
08:00 – 16:35 CET | Stockholm, Sweden
The event caters to life science companies and investors, who will gain insight from each other and engage in thought-provoking discussions.
CEO Bent Frandsen with present at 11:00 CET. For more information and to register, please visit the event website.
17 September 2024 | Danish Stock Seminar for Institutional Investors, hosted by HC Andersen Capital
08:00 – 16:55 | Copenhagen, Denmark
HC Andersen Capital introduces a forum to bring together Danish companies and institutional investors.
CEO Bent Frandsen with present at 9:30 CET. For more information and to register, please contact HC Andersen Capital.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.